ArticleDiscover oncology2025
Identification and characterization of survival-dependent genes in esophageal cancer via the DepMap database: unraveling their association with immune infiltration.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MTG2 as a Causal and Druggable Target in Uveal Melanoma via Mitochondrial DNA Dynamics: Evidence From Functional Validation and DMSA Identification.Investigative ophthalmology & visual science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundEsophageal cancer ranks as the 11th most diagnosed cancer worldwide and the 7th leading cause of cancer-related deaths, mainly due to late-stage diagnosis. Identifying novel biomarkers is essential for enhancing prognostic evaluations and targeting patients for immunotherapy.
methodsWe used the DepMap database to identify survival-dependent genes in esophageal carcinoma cells. A prognostic model was developed using univariate and multivariate Cox regression and LASSO, validated with the GEO dataset. WGCNA and GSEA analyses were conducted to explore mechanisms, alongside ESTIMATE and ssGSEA for prognosis.
resultsWe constructed a novel four-gene prognostic signature (CPSF6, IGBP1, MTG2, TCP1) based on SDG expression and survival data. This signature stratified esophageal cancer patients into high- and low-risk groups with significantly different survival, with the high-risk group showing shorter survival. WGCNA and GSEA analyses linked prognosis to immune pathways, including interferon-γ response and IL6-JAK-STAT3 signaling. ssGSEA revealed reduced infiltration of 19 immune cell types in high-risk patients, and ESTIMATE analysis confirmed the association between immune infiltration and poor prognosis.
conclusionThis study establishes a four-gene survival signature for esophageal cancer that distinguishes high-risk from low-risk populations, providing novel prognostic indicators. Immune response pathways were downregulated in high-risk patients, offering potential targets for understanding esophageal cancer mechanisms and developing immunotherapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.